Stephen Ruddy - Deciphera Pharmaceuticals VP Officer
| DCPHDelisted Stock | USD 13.32 0.36 2.63% |
VP
Dr. Stephen B. Ruddy Ph.D., is Chief Technical Officer of the company since May 2018. He has more than 25 years of global pharmaceutical management and leadership experience in smallmolecule and biologics development and manufacturing. Prior to joining Deciphera, Dr. Ruddy served as Vice President of Pharmaceutical Development at TESARO, Inc., an oncologyfocused biopharmaceutical company, from January 2015 to May 2018. Before joining TESARO, Dr. Ruddy served as Senior Director, Technology Development Operations at ViroPharma Inc., from March 2012 to December 2014, prior to and following its acquisition by Shire plc. Prior to joining ViroPharma, he served for 19 years in roles of increasing responsibility in chemistry, manufacturing and control, or CMC, at Elan Corporation plc, Merck Co. Inc., NanoSystems LLC and Sterling Winthrop Pharmaceuticals since 2018.
| Age | 60 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 781 209 6400 |
| Web | https://www.deciphera.com |
Deciphera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2662) % which means that it has lost $0.2662 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5037) %, meaning that it created substantial loss on money invested by shareholders. Deciphera Pharmaceuticals' management efficiency ratios could be used to measure how well Deciphera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Deciphera Pharmaceuticals LLC currently holds 25.88 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Deciphera Pharmaceuticals has a current ratio of 5.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Deciphera Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 13 records | VP Age | ||
| Mona Desai | Phibro Animal Health | N/A | |
| Meredith JD | ANI Pharmaceuticals | 51 | |
| MBA MS | Ironwood Pharmaceuticals | N/A | |
| Judith Weinstein | Phibro Animal Health | 56 | |
| Christiane Honisch | Evotec SE ADR | N/A | |
| Shirley JD | Collegium Pharmaceutical | 41 | |
| William JD | Prestige Brand Holdings | 60 | |
| Gregory Davis | Avadel Pharmaceuticals PLC | 60 | |
| MPH MD | Ironwood Pharmaceuticals | N/A | |
| Thomas McHugh | Avadel Pharmaceuticals PLC | 60 | |
| David JD | Alkermes Plc | 53 | |
| Anthony CPA | Phibro Animal Health | 55 | |
| Meredith Cook | ANI Pharmaceuticals | 50 | |
Management Performance
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 |
Deciphera Pharmaceuticals Leadership Team
Elected by the shareholders, the Deciphera Pharmaceuticals' board of directors comprises two types of representatives: Deciphera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Deciphera. The board's role is to monitor Deciphera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Deciphera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Deciphera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Flynn, Founder, Chief Scientific Officer | ||
| Daniel Martin, Chief Commercial Officer | ||
| Margarida Duarte, Senior International | ||
| Stephen Ruddy, VP Officer | ||
| Kevin Brodbeck, Senior Officer | ||
| Lisa Price, Senior Officer | ||
| Matthew MD, Executive Officer | ||
| Jeffrey JD, Senior Counsel | ||
| Steven Hoerter, President CEO | ||
| Dashyant Dhanak, Executive Officer | ||
| Thomas JD, CFO VP | ||
| Jennifer Larson, Senior Relations | ||
| Jama Pitman, Quality Regulatory |
Deciphera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Deciphera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.09) % | |||
| Operating Margin | (1.09) % | |||
| Current Valuation | 1.97 B | |||
| Shares Outstanding | 86.48 M | |||
| Shares Owned By Insiders | 28.48 % | |||
| Shares Owned By Institutions | 72.03 % | |||
| Number Of Shares Shorted | 3.92 M | |||
| Price To Earning | (6.78) X |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |